1-5 of 5
Jacqueline C. Barrientos
Close
Sort by
Journal Articles

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry

Clinical Trials & Observations
Anthony R. Mato, Nilanjan Ghosh, Jeff P. Sharman, Danielle Brander, Meghan Gutierrez, Qing Huang, Linda H. Wu, Alex Young, Sandhya Upasani, Maoko Naganuma, Jacqueline C. Barrientos
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4760–4764.
https://doi.org/10.1182/bloodadvances.2022008068
Published: 2023
Includes: Supplemental data
Journal Articles

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019

Adam S. Kittai, Ying Huang, Seema A. Bhat, Electra D. Paskett, Kerry A. Rogers, Jacqueline C. Barrientos, James L. Fisher, Jennifer A. Woyach
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2575–2579.
https://doi.org/10.1182/bloodadvances.2022008643
Published: 2023
Journal Articles

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Clinical Trials & Observations
Ariela Noy, Sven de Vos, Morton Coleman, Peter Martin, Christopher R. Flowers, Catherine Thieblemont, Franck Morschhauser, Graham P. Collins, Shuo Ma, Shachar Peles, Stephen D. Smith, Jacqueline C. Barrientos, Elizabeth Chong, Shiquan Wu, Leo W.-K. Cheung, Kevin Kwei, Bernhard Hauns, Israel Arango-Hisijara, Robert Chen
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5773–5784.
https://doi.org/10.1182/bloodadvances.2020003121
Published: 2020
Includes: Supplemental data
Journal Articles

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Clinical Trials & Observations
Steven E. Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard R. Furman, Jan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James, Susan M. O’Brien
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1799–1807.
https://doi.org/10.1182/bloodadvances.2018028761
Published: 2019
Includes: Supplemental data
Journal Articles

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood Advances
Blood Adv (2016) 1 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2016000976
Published: 2016
Includes: Supplemental data